Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 5, 1998, Pages 353-360

  Son, Young Sook ^b   Suh, Jae Myoung ^a   Ahn, Soo Hyun ^a   Kim, Jun Chul ^a   Yi, Jae Youn ^c   Hur, Kyu Chung ^c   Hong, Weon Seon ^d   Muller, Mark T ^e   Chung, In Kwon ^a  

^a Yonsei University   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

^c Ewha Womans University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

Adriamycin; Anticancer drug; Covalent cleavable complex; Etoposide; Topoisomerase II

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; MITOMYCIN C; MITOXANTRONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL GROWTH; CONTROLLED STUDY; COVALENT BOND; CROSS RESISTANCE; DRUG RESISTANCE; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME REPRESSION; HUMANS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031905844     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050751     Document Type: Article

References (29)

1. Carmichael J, Mitchell JG, DeGraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E, Minna JD (1985) Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 57: 540
2. Chandler LA, DeClerck YA, Bogenmann E, Jones PA (1986) Patterns of DNA methylation and gene expression in human tumor cell lines. Cancer Res 46: 2944
3. Chung IK, Muller MT (1991) Aggregates of oligo(dG) bind and inhibit topoisomerase II activity and induce formation of large networks. J Biol Chem 266: 9508
4. Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK (1989) Characterization and immunochemical identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 86: 9431
5. Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP, Beck WT (1993) Single-strand conformational polymorphism analysis of the Mr 170 000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res 53: 1373
6. De Jong S, Zijlstra JG, Vies EGE de, Mulder NH (1990) Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304
7. DeVore RF, Corbett AH, Osheroff N (1992) Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinyl-amino)methane-sulfon-m-ansidide. Cancer Res 52: 2156
8. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirbelli CK (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28: 8154
9. Evans CD, Mirski SEL, Danks MK, Cole SPC (1994) Reduced levels of topoisomerase IIα and IIβ in a multidrug-resistant lung-cancer cell line. Cancer Chemother Pharmacol 34: 242
10. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G (1992) Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666
11. Hochhauser D, Stanway CA, Harris AL, Hickson ID (1992) Cloning and characterization of the 5′-flanking region of the human topoisomerase IIα gene. J Biol Chem 267: 18961
12. Hong WS, Saijo N, Yasutsuna S, Minato K, Nakano H, Nakagawa K, Fujiwara Y, Nomura K, Twentyman PR (1988) Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer 41: 462
13. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351
14. McPherson JP, Brown GA, Goldenberg GJ (1993) Characterization of a DNA topoisomerase IIα gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIα and the retinoic acid receptor α locus. Cancer Res 53: 5885
15. Meijor C, Mulder NH, Timmer-Bosscha H, Zijlstra JG, Vries EGE de (1987) Role of free radical in an adriamycin-resistant human small cell lung cancer cell line. Cancer Res 47: 4613
16. Mirski SEL, Evans CD, Almquist KC, Slovak ML, Cole SPC (1993) Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 53: 4866
17. Moscow JA, Cowan KH (1988) Multidrug resistance. J Natl Cancer Inst 80: 14
18. Muller MT, Mehta VB (1988) DNase I hypersensitivity is independent of endogenous topoisomerase II activity during chicken erythrocyte differentiation. Mol Cell Biol 8:3661
19. Muller MT, Spitzner JR, DiDonato JA, Mehta VB, Tsutsui K (1988) Single-strand DNA cleavages by eukaryotic topoisomerase II. Biochemistry 27: 8369
20. Roca J, Wang JC (1994) DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 77: 609
21. Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE (1989) Adriamycin activation and oxygen free radical formation in human breast tumor cell: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 49: 3844
22. Takano H, Kohno K, Ono M, Uchida Y, Kuwuno M (1991) Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human cancer KB cells. Cancer Res 51: 3947
23. Tan KB, Mattern MR, Eng W-K, McCabe FL, Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732
24. Tan KB, Dorman TE, Falls KM, Chung TDY, Mirabelli CK, Crooke ST, Mao J-I (1992) Topoisomerase IIα and topoisomerase IIβ genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 52: 231
25. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466
26. Tritton TR (1991) Cell surface actions of adriamycin. Pharmacol Ther 49: 293
27. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65: 635
28. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH (1991) Proliferation and cell cycle-dependent differences in expression of the 170 kilodalton and the 180 kilodalton forms of DNA topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2: 209
29. Yi JY, Son YS, Hur KC, Hong SI, Lee YS, Park SC, Hong WS (1996) Bcl-2 and GST-π overexpression in H69/CDDP and enhanced superoxide dismutase activity in PC9/CDDP and PC14/CDDP may play roles in their cisplatin resistance. Mol Cells 6: 444